CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals
Abstract Human immunodeficiency virus type 1 (HIV-1) canarypox vaccines are safe but poorly immunogenic. CD40 ligand (CD40L), a member of the tumor necrosis factor superfamily (TNFSF), is a pivotal costimulatory molecule for immune responses. To explore whether CD40L can be used as an adjuvant for H...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2008-07, Vol.26 (32), p.4062-4072 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4072 |
|---|---|
| container_issue | 32 |
| container_start_page | 4062 |
| container_title | Vaccine |
| container_volume | 26 |
| creator | Liu, Jun Yu, Qigui Stone, Geoffrey W Yue, Feng Yun Ngai, Nicholas Jones, R. Brad Kornbluth, Richard S Ostrowski, Mario A |
| description | Abstract Human immunodeficiency virus type 1 (HIV-1) canarypox vaccines are safe but poorly immunogenic. CD40 ligand (CD40L), a member of the tumor necrosis factor superfamily (TNFSF), is a pivotal costimulatory molecule for immune responses. To explore whether CD40L can be used as an adjuvant for HIV-1 canarypox vaccine, we constructed recombinant canarypox viruses expressing CD40L. Co-immunization of mice with CD40L expressing canarypox and the canarypox vaccine expressing HIV-1 proteins, vCP1452, augmented HIV-1 specific cytotoxic T lymphocyte (CTL) responses in terms of frequency, polyfunctionality and interleukin (IL)-7 receptor α chain (IL-7Rα, CD127) expression. In addition, CD40L expressed from canarypox virus could significantly augment CD4+ T cell responses against HIV-1 in mice. CD40L expressed from canarypox virus matured human monocyte-derived dendritic cells (MDDCs) in a tumor necrosis factor-α (TNF-α) independent manner, which underwent less apoptosis, and could expand ex vivo Epstein–Barr virus (EBV)-specific CTL responses from healthy human individuals and ex vivo HIV-1-specific CTL responses from HIV-1-infected individuals in the presence or absence of CD4+ T cells. Taken together, our results suggest that CD40L incorporation into poxvirus vectors could be used as a strategy to enhance their immunogenicity. |
| doi_str_mv | 10.1016/j.vaccine.2008.05.018 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3060027</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X08005914</els_id><sourcerecordid>69324489</sourcerecordid><originalsourceid>FETCH-LOGICAL-c578t-aaa7a9fc79dd61c20ab957fd22f777f62b66d3253c325d2566e231d41e6801883</originalsourceid><addsrcrecordid>eNqFU8Fu1DAQjRCIlsIngCwhuNAsthMnzqVotQVaaSUOlIqb5bUnXS-JvbWTqPvffAAOWW1LL1ziePw8897Mc5K8JnhGMCk-bmaDVMpYmFGM-QyzGSb8SXJMeJmllBH-NDnGtMjTnOCfR8mLEDYYY5aR6nlyRDgraNwcJ78X5zleIrjbeggBNKq9a1G3BqSklX63dXdoANU5f4rmy-v54nQ8QCvnQodM2_bW3YA1ynQ75Gp0cXmdkodXJ47IWNQaBUhajcCupY3_Y5EYH0zn3UhA2mCcHbMMxssGhS0oUxuFFuf8A7pCCpoGtdA6v0OR7NbZAGHi-7dsamwdmUYNY5Up1NtD0FhtBqN72YSXybM6LvBqv54kP758vlpcpMtvXy8X82WqWMm7VEpZyqpWZaV1QRTFclWxstaU1mVZ1gVdFYXOKMtU_GjKigJoRnROoOBxGDw7Sc6mvNt-1YJWYLsoTGy9aWN_hJNG_HtizVrcuEFkuMCYljHB-30C7257CJ1oTRj7IC24Poiiymie8yoC3z4CblzvbRQnCGOc55zyLKLYhFLeheChPlAhWIyuEhuxn5gYXSUwE1FIvPfmoY77W3sbRcC7PUAGJZvaxwGbcMBFDCsZGXGfJhzErg8GvAjKQDSDNj5OSWhn_kvl7FEG1ZjoP9n8gh2Ee9UiUIHF9_EJjC8A82j-iuTZH4fjBVg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1558848283</pqid></control><display><type>article</type><title>CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>ProQuest Central</source><creator>Liu, Jun ; Yu, Qigui ; Stone, Geoffrey W ; Yue, Feng Yun ; Ngai, Nicholas ; Jones, R. Brad ; Kornbluth, Richard S ; Ostrowski, Mario A</creator><creatorcontrib>Liu, Jun ; Yu, Qigui ; Stone, Geoffrey W ; Yue, Feng Yun ; Ngai, Nicholas ; Jones, R. Brad ; Kornbluth, Richard S ; Ostrowski, Mario A</creatorcontrib><description>Abstract Human immunodeficiency virus type 1 (HIV-1) canarypox vaccines are safe but poorly immunogenic. CD40 ligand (CD40L), a member of the tumor necrosis factor superfamily (TNFSF), is a pivotal costimulatory molecule for immune responses. To explore whether CD40L can be used as an adjuvant for HIV-1 canarypox vaccine, we constructed recombinant canarypox viruses expressing CD40L. Co-immunization of mice with CD40L expressing canarypox and the canarypox vaccine expressing HIV-1 proteins, vCP1452, augmented HIV-1 specific cytotoxic T lymphocyte (CTL) responses in terms of frequency, polyfunctionality and interleukin (IL)-7 receptor α chain (IL-7Rα, CD127) expression. In addition, CD40L expressed from canarypox virus could significantly augment CD4+ T cell responses against HIV-1 in mice. CD40L expressed from canarypox virus matured human monocyte-derived dendritic cells (MDDCs) in a tumor necrosis factor-α (TNF-α) independent manner, which underwent less apoptosis, and could expand ex vivo Epstein–Barr virus (EBV)-specific CTL responses from healthy human individuals and ex vivo HIV-1-specific CTL responses from HIV-1-infected individuals in the presence or absence of CD4+ T cells. Taken together, our results suggest that CD40L incorporation into poxvirus vectors could be used as a strategy to enhance their immunogenicity.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2008.05.018</identifier><identifier>PMID: 18562053</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Adjuvants, Immunologic ; AIDS ; AIDS Vaccines - chemistry ; AIDS Vaccines - immunology ; Allergy and Immunology ; Animals ; Apoptosis ; Apoptosis - drug effects ; Applied microbiology ; Biological and medical sciences ; Canarypox vector ; Canarypox virus - immunology ; Canarypox virus - metabolism ; CD40 Ligand - metabolism ; CD40 Ligand - pharmacology ; CD8-Positive T-Lymphocytes - drug effects ; CD8-Positive T-Lymphocytes - immunology ; Colleges & universities ; Cytotoxic T cell ; Cytotoxicity ; Dendritic Cells - drug effects ; Expansion ; Female ; Flow cytometry ; Fundamental and applied biological sciences. Psychology ; HIV ; HIV Infections - genetics ; HIV Infections - immunology ; HIV-1 - immunology ; Human immunodeficiency virus ; Human viral diseases ; Humans ; Immune system ; Immunization ; Immunogenicity ; Infectious diseases ; Laboratories ; Lymphocytes ; Medical sciences ; Mice ; Mice, Inbred BALB C ; Microbiology ; Miscellaneous ; Proteins ; T cell receptors ; Vaccines ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids ; Viral Vaccines - metabolism ; Virology ; Viruses</subject><ispartof>Vaccine, 2008-07, Vol.26 (32), p.4062-4072</ispartof><rights>Elsevier Ltd</rights><rights>2008 Elsevier Ltd</rights><rights>2008 INIST-CNRS</rights><rights>Copyright Elsevier Limited Jul 29, 2008</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c578t-aaa7a9fc79dd61c20ab957fd22f777f62b66d3253c325d2566e231d41e6801883</citedby><cites>FETCH-LOGICAL-c578t-aaa7a9fc79dd61c20ab957fd22f777f62b66d3253c325d2566e231d41e6801883</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1558848283?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20557513$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18562053$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liu, Jun</creatorcontrib><creatorcontrib>Yu, Qigui</creatorcontrib><creatorcontrib>Stone, Geoffrey W</creatorcontrib><creatorcontrib>Yue, Feng Yun</creatorcontrib><creatorcontrib>Ngai, Nicholas</creatorcontrib><creatorcontrib>Jones, R. Brad</creatorcontrib><creatorcontrib>Kornbluth, Richard S</creatorcontrib><creatorcontrib>Ostrowski, Mario A</creatorcontrib><title>CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Abstract Human immunodeficiency virus type 1 (HIV-1) canarypox vaccines are safe but poorly immunogenic. CD40 ligand (CD40L), a member of the tumor necrosis factor superfamily (TNFSF), is a pivotal costimulatory molecule for immune responses. To explore whether CD40L can be used as an adjuvant for HIV-1 canarypox vaccine, we constructed recombinant canarypox viruses expressing CD40L. Co-immunization of mice with CD40L expressing canarypox and the canarypox vaccine expressing HIV-1 proteins, vCP1452, augmented HIV-1 specific cytotoxic T lymphocyte (CTL) responses in terms of frequency, polyfunctionality and interleukin (IL)-7 receptor α chain (IL-7Rα, CD127) expression. In addition, CD40L expressed from canarypox virus could significantly augment CD4+ T cell responses against HIV-1 in mice. CD40L expressed from canarypox virus matured human monocyte-derived dendritic cells (MDDCs) in a tumor necrosis factor-α (TNF-α) independent manner, which underwent less apoptosis, and could expand ex vivo Epstein–Barr virus (EBV)-specific CTL responses from healthy human individuals and ex vivo HIV-1-specific CTL responses from HIV-1-infected individuals in the presence or absence of CD4+ T cells. Taken together, our results suggest that CD40L incorporation into poxvirus vectors could be used as a strategy to enhance their immunogenicity.</description><subject>Adjuvants, Immunologic</subject><subject>AIDS</subject><subject>AIDS Vaccines - chemistry</subject><subject>AIDS Vaccines - immunology</subject><subject>Allergy and Immunology</subject><subject>Animals</subject><subject>Apoptosis</subject><subject>Apoptosis - drug effects</subject><subject>Applied microbiology</subject><subject>Biological and medical sciences</subject><subject>Canarypox vector</subject><subject>Canarypox virus - immunology</subject><subject>Canarypox virus - metabolism</subject><subject>CD40 Ligand - metabolism</subject><subject>CD40 Ligand - pharmacology</subject><subject>CD8-Positive T-Lymphocytes - drug effects</subject><subject>CD8-Positive T-Lymphocytes - immunology</subject><subject>Colleges & universities</subject><subject>Cytotoxic T cell</subject><subject>Cytotoxicity</subject><subject>Dendritic Cells - drug effects</subject><subject>Expansion</subject><subject>Female</subject><subject>Flow cytometry</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>HIV</subject><subject>HIV Infections - genetics</subject><subject>HIV Infections - immunology</subject><subject>HIV-1 - immunology</subject><subject>Human immunodeficiency virus</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Immune system</subject><subject>Immunization</subject><subject>Immunogenicity</subject><subject>Infectious diseases</subject><subject>Laboratories</subject><subject>Lymphocytes</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Microbiology</subject><subject>Miscellaneous</subject><subject>Proteins</subject><subject>T cell receptors</subject><subject>Vaccines</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><subject>Viral Vaccines - metabolism</subject><subject>Virology</subject><subject>Viruses</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFU8Fu1DAQjRCIlsIngCwhuNAsthMnzqVotQVaaSUOlIqb5bUnXS-JvbWTqPvffAAOWW1LL1ziePw8897Mc5K8JnhGMCk-bmaDVMpYmFGM-QyzGSb8SXJMeJmllBH-NDnGtMjTnOCfR8mLEDYYY5aR6nlyRDgraNwcJ78X5zleIrjbeggBNKq9a1G3BqSklX63dXdoANU5f4rmy-v54nQ8QCvnQodM2_bW3YA1ynQ75Gp0cXmdkodXJ47IWNQaBUhajcCupY3_Y5EYH0zn3UhA2mCcHbMMxssGhS0oUxuFFuf8A7pCCpoGtdA6v0OR7NbZAGHi-7dsamwdmUYNY5Up1NtD0FhtBqN72YSXybM6LvBqv54kP758vlpcpMtvXy8X82WqWMm7VEpZyqpWZaV1QRTFclWxstaU1mVZ1gVdFYXOKMtU_GjKigJoRnROoOBxGDw7Sc6mvNt-1YJWYLsoTGy9aWN_hJNG_HtizVrcuEFkuMCYljHB-30C7257CJ1oTRj7IC24Poiiymie8yoC3z4CblzvbRQnCGOc55zyLKLYhFLeheChPlAhWIyuEhuxn5gYXSUwE1FIvPfmoY77W3sbRcC7PUAGJZvaxwGbcMBFDCsZGXGfJhzErg8GvAjKQDSDNj5OSWhn_kvl7FEG1ZjoP9n8gh2Ee9UiUIHF9_EJjC8A82j-iuTZH4fjBVg</recordid><startdate>20080729</startdate><enddate>20080729</enddate><creator>Liu, Jun</creator><creator>Yu, Qigui</creator><creator>Stone, Geoffrey W</creator><creator>Yue, Feng Yun</creator><creator>Ngai, Nicholas</creator><creator>Jones, R. Brad</creator><creator>Kornbluth, Richard S</creator><creator>Ostrowski, Mario A</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20080729</creationdate><title>CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals</title><author>Liu, Jun ; Yu, Qigui ; Stone, Geoffrey W ; Yue, Feng Yun ; Ngai, Nicholas ; Jones, R. Brad ; Kornbluth, Richard S ; Ostrowski, Mario A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c578t-aaa7a9fc79dd61c20ab957fd22f777f62b66d3253c325d2566e231d41e6801883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adjuvants, Immunologic</topic><topic>AIDS</topic><topic>AIDS Vaccines - chemistry</topic><topic>AIDS Vaccines - immunology</topic><topic>Allergy and Immunology</topic><topic>Animals</topic><topic>Apoptosis</topic><topic>Apoptosis - drug effects</topic><topic>Applied microbiology</topic><topic>Biological and medical sciences</topic><topic>Canarypox vector</topic><topic>Canarypox virus - immunology</topic><topic>Canarypox virus - metabolism</topic><topic>CD40 Ligand - metabolism</topic><topic>CD40 Ligand - pharmacology</topic><topic>CD8-Positive T-Lymphocytes - drug effects</topic><topic>CD8-Positive T-Lymphocytes - immunology</topic><topic>Colleges & universities</topic><topic>Cytotoxic T cell</topic><topic>Cytotoxicity</topic><topic>Dendritic Cells - drug effects</topic><topic>Expansion</topic><topic>Female</topic><topic>Flow cytometry</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>HIV</topic><topic>HIV Infections - genetics</topic><topic>HIV Infections - immunology</topic><topic>HIV-1 - immunology</topic><topic>Human immunodeficiency virus</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Immune system</topic><topic>Immunization</topic><topic>Immunogenicity</topic><topic>Infectious diseases</topic><topic>Laboratories</topic><topic>Lymphocytes</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Microbiology</topic><topic>Miscellaneous</topic><topic>Proteins</topic><topic>T cell receptors</topic><topic>Vaccines</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><topic>Viral Vaccines - metabolism</topic><topic>Virology</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, Jun</creatorcontrib><creatorcontrib>Yu, Qigui</creatorcontrib><creatorcontrib>Stone, Geoffrey W</creatorcontrib><creatorcontrib>Yue, Feng Yun</creatorcontrib><creatorcontrib>Ngai, Nicholas</creatorcontrib><creatorcontrib>Jones, R. Brad</creatorcontrib><creatorcontrib>Kornbluth, Richard S</creatorcontrib><creatorcontrib>Ostrowski, Mario A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>ProQuest Biological Science Journals</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Jun</au><au>Yu, Qigui</au><au>Stone, Geoffrey W</au><au>Yue, Feng Yun</au><au>Ngai, Nicholas</au><au>Jones, R. Brad</au><au>Kornbluth, Richard S</au><au>Ostrowski, Mario A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2008-07-29</date><risdate>2008</risdate><volume>26</volume><issue>32</issue><spage>4062</spage><epage>4072</epage><pages>4062-4072</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>Abstract Human immunodeficiency virus type 1 (HIV-1) canarypox vaccines are safe but poorly immunogenic. CD40 ligand (CD40L), a member of the tumor necrosis factor superfamily (TNFSF), is a pivotal costimulatory molecule for immune responses. To explore whether CD40L can be used as an adjuvant for HIV-1 canarypox vaccine, we constructed recombinant canarypox viruses expressing CD40L. Co-immunization of mice with CD40L expressing canarypox and the canarypox vaccine expressing HIV-1 proteins, vCP1452, augmented HIV-1 specific cytotoxic T lymphocyte (CTL) responses in terms of frequency, polyfunctionality and interleukin (IL)-7 receptor α chain (IL-7Rα, CD127) expression. In addition, CD40L expressed from canarypox virus could significantly augment CD4+ T cell responses against HIV-1 in mice. CD40L expressed from canarypox virus matured human monocyte-derived dendritic cells (MDDCs) in a tumor necrosis factor-α (TNF-α) independent manner, which underwent less apoptosis, and could expand ex vivo Epstein–Barr virus (EBV)-specific CTL responses from healthy human individuals and ex vivo HIV-1-specific CTL responses from HIV-1-infected individuals in the presence or absence of CD4+ T cells. Taken together, our results suggest that CD40L incorporation into poxvirus vectors could be used as a strategy to enhance their immunogenicity.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>18562053</pmid><doi>10.1016/j.vaccine.2008.05.018</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2008-07, Vol.26 (32), p.4062-4072 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3060027 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete; ProQuest Central |
| subjects | Adjuvants, Immunologic AIDS AIDS Vaccines - chemistry AIDS Vaccines - immunology Allergy and Immunology Animals Apoptosis Apoptosis - drug effects Applied microbiology Biological and medical sciences Canarypox vector Canarypox virus - immunology Canarypox virus - metabolism CD40 Ligand - metabolism CD40 Ligand - pharmacology CD8-Positive T-Lymphocytes - drug effects CD8-Positive T-Lymphocytes - immunology Colleges & universities Cytotoxic T cell Cytotoxicity Dendritic Cells - drug effects Expansion Female Flow cytometry Fundamental and applied biological sciences. Psychology HIV HIV Infections - genetics HIV Infections - immunology HIV-1 - immunology Human immunodeficiency virus Human viral diseases Humans Immune system Immunization Immunogenicity Infectious diseases Laboratories Lymphocytes Medical sciences Mice Mice, Inbred BALB C Microbiology Miscellaneous Proteins T cell receptors Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Viral Vaccines - metabolism Virology Viruses |
| title | CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T09%3A47%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CD40L%20expressed%20from%20the%20canarypox%20vector,%20ALVAC,%20can%20boost%20immunogenicity%20of%20HIV-1%20canarypox%20vaccine%20in%20mice%20and%20enhance%20the%20in%20vitro%20expansion%20of%20viral%20specific%20CD8+%20T%20cell%20memory%20responses%20from%20HIV-1-infected%20and%20HIV-1-uninfected%20individuals&rft.jtitle=Vaccine&rft.au=Liu,%20Jun&rft.date=2008-07-29&rft.volume=26&rft.issue=32&rft.spage=4062&rft.epage=4072&rft.pages=4062-4072&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/j.vaccine.2008.05.018&rft_dat=%3Cproquest_pubme%3E69324489%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1558848283&rft_id=info:pmid/18562053&rft_els_id=S0264410X08005914&rfr_iscdi=true |